{"id":115176,"date":"2020-10-29T12:42:08","date_gmt":"2020-10-29T16:42:08","guid":{"rendered":"https:\/\/www.ucf.edu\/news\/?p=115176"},"modified":"2020-10-29T12:42:08","modified_gmt":"2020-10-29T16:42:08","slug":"ucf-researchers-natural-killer-cell-therapy-in-trials-for-treating-covid-19","status":"publish","type":"post","link":"https:\/\/www.ucf.edu\/news\/ucf-researchers-natural-killer-cell-therapy-in-trials-for-treating-covid-19\/","title":{"rendered":"Âé¶¹Ó³»´«Ã½ Researcher’s Natural Killer Cell Therapy In Trials for Treating COVID-19"},"content":{"rendered":"
An immunity-boosting technology developed by the College of Medicine is being tested as a potential weapon in the fight against COVID-19.<\/p>\n
Âé¶¹Ó³»´«Ã½ cancer researcher Alicja Copik created the therapy that stimulates the body\u2019s natural killer (NK) cells with nanoparticles to increase their numbers and killing ability.\u00a0 Kiadis Pharma, one of the world\u2019s largest pharmaceutical companies, has licensed the technology and has it in clinical trials as a therapy for cancer. Now, with $9.5 million in funding from the Department of Defense and the Advanced Regenerative Manufacturing Institute\u2019s (ARMI) BioFabUSA program \u2014 which specializes in tissue engineering \u2014 Kiadis has begun clinical trials using NK cell therapy as a potential treatment for COVID-19 patients with weakened immune systems. The study will also see if the therapy protects high-risk patients against respiratory infections like influenza, either alone or in combination with vaccines and antibodies.<\/p>\n